China Diabetes Type 1 Study (CD1S) by China Alliance for Type 1 Diabetes
NCT ID: NCT05498974
Last Updated: 2022-08-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
20000 participants
OBSERVATIONAL
2022-01-01
2035-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
CD1S compromises a retrospective study enrolling inpatients hospitalized from Jan 1st, 2016 to Dec 31, 2021, and a prospective study beginning from the year 2022.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cohort Study of Patients With Type 1 Diabetes
NCT03610984
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
NCT04096794
Clinical Characteristics of People With Long-term Type 1 Diabetes
NCT05359796
Multicenter Study of Fulminant Type 1 Diabetes in China
NCT05593081
Genetics of Type 1 Diabetes in Chinese Adolescents and Youth
NCT01938365
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Individuals diagnosed with type 1 diabetes
All patients diagnosed with type 1 diabetes of all ages.
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Individuals with diabetes who had an age of onset <= 20 years.
All patients with diabetes who had an age of onset \<= 20 years.
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Standard type 1 diabetes management model constructed by China Alliance for Type 1 Diabetes in each center
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Clinical diagnosis of type 1 diabetes by a specialist
2. Age at onset \< 15 years; no overweight or obesity at onset; previous diabetic ketoacidosis; highest random C-peptide \< 200 pmol/L
3. Initiation and continuation of insulin therapy (except pancreatic or islet transplantation) after diagnosis; positive islet autoantibodies Or 2. Children and adolescents with diabetes mellitus at age of onset \<= 20 years, regardless of type and duration of disease.
Exclusion Criteria
* No insulin dependence for at least 6 months after diagnosis of diabetes mellitus.
* No DKA for 1 month off insulin for those with a history of diabetes \> 1 year. ③ C-peptide \> 800 pmol/L at any time point.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Xiangya Hospital of Central South University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zhiguang Zhou
Director, National Clinical Research Center for Metabolic Diseases
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Zhiguang Zhou, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
The Second Xiangya Hospital, Central South University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Gansu Provincial People's Hospital
Lanzhou, Gansu, China
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Hainan General Hospital
Haikou, Hainan, China
the First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, China
The Second Xiangya Hospital, Central South University
Changsha, Hunan, China
The First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China
Heji Hospital Affiliated to Changzhi Medical College
Changzhi, Shanxi, China
The First Affiliated Hospital of Xinjiang Medical University
Ürümqi, Xinjiang, China
The First People's Hospital of Yunnan
Kunming, Yunnan, China
Zhejiang Provincial People's Hospital
Hangzhou, Zhejiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Jing Liu
Role: primary
Dewen Yan
Role: primary
Huibiao Quan
Role: primary
Hongyu Kuang
Role: primary
Hongwei Jiang
Role: primary
Tao Yang
Role: primary
Xiaohong Niu
Role: primary
Sheng Jiang
Role: primary
Heng Su
Role: primary
Xiaohong Wu
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CD1S
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.